Literature DB >> 11254559

Epitope mapping of monoclonal antibodies capable of neutralizing cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli.

K C Meysick1, M Mills, A D O'Brien.   

Abstract

Cytotoxic necrotizing factor type 1 (CNF1) of uropathogenic Escherichia coli belongs to a family of bacterial toxins that target the small GTP-binding Rho proteins that regulate the actin cytoskeleton. Members of this toxin family typically inactivate Rho; however, CNF1 and the highly related CNF2 activate Rho by deamidation. Other investigators have reported that the first 190 amino acids of CNF1 constitute the cellular binding domain and that the CNF1 enzymatic domain lies within a 300-amino-acid stretch in the C terminus of the toxin. Amino acids 53 to 75 appear to be critical for cell receptor recognition, while amino acids Cys866 and His881 are considered essential for deamidation activity. To delineate further the functional domains of CNF1, we generated 16 monoclonal antibodies (MAbs) against the toxin and used them for epitope mapping studies. Based on Western blot immunoreactivity patterns obtained from a series of truncated CNF1 proteins, this panel of MAbs mapped to epitopes located throughout the toxin, including the binding and enzymatic domains. All MAbs showed reactivity to CNF1 by Western and dot blot analyses. However, only 7 of the 16 MAbs exhibited cross-reactivity with CNF2. Furthermore, only three MAbs demonstrated the capacity to neutralize toxin in either HEp-2 cell assays (inhibition of multinucleation) or 5637 bladder cell assays (inhibition of cytotoxicity). Since CNF1 epitopes recognized by neutralizing MAbs are likely to represent domains or regions necessary for the biological activities of the toxin, the epitopes recognized by these three MAbs, designated JC4 (immunoglobulin G2a [IgG2a]), BF8 (IgA), and NG8 (IgG2a), were more precisely defined. MAbs JC4 and BF8 reacted with epitopes that were common to CNF1 and CNF2 and located within the putative CNF1 binding domain. MAb JC4 recognized an epitope spanning amino acids 169 to 191, whereas MAb BF8 mapped to an epitope between amino acids 135 and 164. Despite the capacity of both MAbs to recognize CNF2 in Western blot analyses, only MAb BF8 neutralized CNF2. MAb NG8 showed reactivity to a CNF1-specific epitope located between amino acids 683 and 730, a region that includes a very small portion of the putative enzymatic domain. Taken together, these findings identify three new regions of the toxin that appear to be critical for the biological activity of CNF1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254559      PMCID: PMC98131          DOI: 10.1128/IAI.69.4.2066-2074.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  The 5' region of cnf1 harbours a translational regulatory mechanism for CNF1 synthesis and encodes the cell-binding domain of the toxin.

Authors:  A Fabbri; M Gauthier; P Boquet
Journal:  Mol Microbiol       Date:  1999-07       Impact factor: 3.501

2.  Identification of the region of rho involved in substrate recognition by Escherichia coli cytotoxic necrotizing factor 1 (CNF1).

Authors:  M Lerm; G Schmidt; U M Goehring; J Schirmer; K Aktories
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

Review 3.  Bacterial protein toxins targeting rho GTPases.

Authors:  M Lerm; G Schmidt; K Aktories
Journal:  FEMS Microbiol Lett       Date:  2000-07-01       Impact factor: 2.742

4.  Deamidation of RhoA glutamine 63 by the Escherichia coli CNF1 toxin requires a short sequence of the GTPase switch 2 domain.

Authors:  G Flatau; L Landraud; P Boquet; M Bruzzone; P Munro
Journal:  Biochem Biophys Res Commun       Date:  2000-01-19       Impact factor: 3.575

5.  Identification of the C-terminal part of Bordetella dermonecrotic toxin as a transglutaminase for rho GTPases.

Authors:  G Schmidt; U M Goehring; J Schirmer; M Lerm; K Aktories
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

6.  Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism.

Authors:  M Mills; K C Meysick; A D O'Brien
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

7.  Reduced pH causes structural changes in the potent mitogenic toxin of Pasteurella multocida.

Authors:  M G Smyth; I G Sumner; A J Lax
Journal:  FEMS Microbiol Lett       Date:  1999-11-01       Impact factor: 2.742

8.  Cytotoxic necrotizing factor type 2 produced by pathogenic Escherichia coli deamidates a gln residue in the conserved G-3 domain of the rho family and preferentially inhibits the GTPase activity of RhoA and rac1.

Authors:  M Sugai; K Hatazaki; A Mogami; H Ohta; S Y Pérès; F Hérault; Y Horiguchi; M Masuda; Y Ueno; H Komatsuzawa; H Suginaka; E Oswald
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

9.  Activation of rho through a cross-link with polyamines catalyzed by Bordetella dermonecrotizing toxin.

Authors:  M Masuda; L Betancourt; T Matsuzawa; T Kashimoto; T Takao; Y Shimonishi; Y Horiguchi
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

10.  Identification of functional domains of Bordetella dermonecrotizing toxin.

Authors:  T Kashimoto; J Katahira; W R Cornejo; M Masuda; A Fukuoh; T Matsuzawa; T Ohnishi; Y Horiguchi
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

View more
  10 in total

1.  Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.

Authors:  Mark A Smith; Rebecca A Weingarten; Lisa M Russo; Christy L Ventura; Alison D O'Brien
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

2.  Two domains of cytotoxic necrotizing factor type 1 bind the cellular receptor, laminin receptor precursor protein.

Authors:  Beth A McNichol; Susan B Rasmussen; Humberto M Carvalho; Karen C Meysick; Alison D O'Brien
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

3.  Cleavage of Escherichia coli cytotoxic necrotizing factor 1 is required for full biologic activity.

Authors:  Zeynep Knust; Britta Blumenthal; Klaus Aktories; Gudula Schmidt
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

4.  Cytotoxic necrotizing factor type 1-neutralizing monoclonal antibody NG8 recognizes three amino acids in a C-terminal region of the toxin and reduces toxin binding to HEp-2 cells.

Authors:  Kerian K Grande; Karen C Meysick; Susan B Rasmussen; Alison D O'Brien
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

5.  Ferredoxin is involved in secretion of cytotoxic necrotizing factor 1 across the cytoplasmic membrane in Escherichia coli K1.

Authors:  Hao Yu; Kwang Sik Kim
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

Review 6.  Cellular and molecular action of the mitogenic protein-deamidating toxin from Pasteurella multocida.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  FEBS J       Date:  2011-05-31       Impact factor: 5.542

7.  Yersinia pseudotuberculosis produces a cytotoxic necrotizing factor.

Authors:  Hank A Lockman; Rebecca A Gillespie; Beth D Baker; Elizabeth Shakhnovich
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

8.  mRNA context dependent regulation of cytotoxic necrotizing factor 1 translation by GidA, a tRNA modification enzyme in Escherichia coli.

Authors:  Hao Yu; Kwang Sik Kim
Journal:  Gene       Date:  2011-10-13       Impact factor: 3.688

9.  YgfZ contributes to secretion of cytotoxic necrotizing factor 1 into outer-membrane vesicles in Escherichia coli.

Authors:  Hao Yu; Kwang Sik Kim
Journal:  Microbiology       Date:  2011-12-15       Impact factor: 2.777

10.  Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice.

Authors:  Yarery C Smith; Susan B Rasmussen; Kerian K Grande; Richard M Conran; Alison D O'Brien
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.